Stereotaxis Inc. (NYSEAMERICAN:STXS) Short Interest Update

Stereotaxis Inc. (NYSEAMERICAN:STXS) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 3,271,536 shares, an increase of 21.2% from the January 29th total of 2,699,750 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average daily volume of 542,840 shares, the short-interest ratio is currently 6.0 days. Based on an average daily volume of 542,840 shares, the short-interest ratio is currently 6.0 days. Approximately 4.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Stereotaxis

A number of institutional investors have recently added to or reduced their stakes in STXS. WealthPLAN Partners LLC acquired a new stake in Stereotaxis during the 4th quarter valued at approximately $29,000. SG Americas Securities LLC acquired a new stake in shares of Stereotaxis during the fourth quarter worth approximately $33,000. BNP Paribas Financial Markets increased its stake in shares of Stereotaxis by 106.5% in the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after buying an additional 5,910 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Stereotaxis in the third quarter worth $38,000. Finally, HRT Financial LP acquired a new stake in Stereotaxis in the fourth quarter valued at $42,000. Institutional investors and hedge funds own 45.35% of the company’s stock.

Stereotaxis Price Performance

NYSEAMERICAN:STXS opened at $2.19 on Friday. The business’s 50-day moving average is $2.32 and its two-hundred day moving average is $2.59. The firm has a market capitalization of $204.37 million, a PE ratio of -7.82 and a beta of 1.38. Stereotaxis has a 12 month low of $1.54 and a 12 month high of $3.59.

Wall Street Analyst Weigh In

STXS has been the topic of a number of research analyst reports. Roth Mkm reissued a “buy” rating and issued a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 12th. Citizens Jmp started coverage on Stereotaxis in a report on Tuesday, December 16th. They issued a “market outperform” rating and a $4.00 target price on the stock. Finally, Citigroup started coverage on Stereotaxis in a research report on Tuesday, December 16th. They set an “outperform” rating for the company. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Stereotaxis has a consensus rating of “Buy” and an average price target of $4.00.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.